glabridin has been researched along with Obesity in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YH; Hung, HY | 1 |
| Choi, LS; Chung, JW; Im, JH; Jo, IG; Kang, KS; Kim, J; Yoo, SK | 1 |
| Choe, SS; Hyun, DH; Jang, H; Jeong, HW; Jeong, KH; Jo, H; Kim, J; Kim, JB; Kwak, TH; Lee, JW; Man Kim, J; Park, MG; Tadi, S | 1 |
1 review(s) available for glabridin and Obesity
| Article | Year |
|---|---|
Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
Topics: Animals; Anti-Obesity Agents; Drug Discovery; Obesity; Phytochemicals | 2022 |
2 other study(ies) available for glabridin and Obesity
| Article | Year |
|---|---|
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Diet, High-Fat; Energy Metabolism; Fatty Liver; Isoflavones; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Phenols; Structure-Activity Relationship; Weight Loss | 2021 |
AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity.
Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Body Weight; Fatty Acids; Isoflavones; Lipid Metabolism; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Phenols; Phosphorylation | 2012 |